$MDGL

3 stories mentioning MDGLUpdated 26d ago

Every FINWIRES story that references MDGL, newest first.

Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients

Madrigal Pharmaceuticals (MDGL) said Wednesday that a new analyses of phase 3 trial data and real-world evidence showed that Rezdiffra reduced markers of cardiovascular and liver-related risk in patients with metabolic dysfunction-associated steatohepatitis (MASH).The drug improved atherogenic lipid profiles associated with cardiovascular risk, according to a secondary analysis of phase 3 data, the company said.In patients with well-compensated MASH cirrhosis, Rezdiffra also improved a risk score that predicts the probability of experiencing severe liver-related events, Madrigal said.Price: $532.02, Change: $+7.74, Percent Change: +1.48%

$MDGL

Insider Trading27d ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $2,928,716, According to a Recent SEC Filing

Richard S Levy, Director, on May 22, 2026, sold 5,682 shares in Madrigal Pharmaceuticals (MDGL) for $2,928,716. Following the Form 4 filing with the SEC, Levy has control over a total of 22,015 common shares of the company, with 22,015 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1157601/000162828026037830/xslF345X05/wk-form4_1779487311.xml

$MDGL

Wire48d ago

Arrowhead Signs Deal With Madrigal to License Clinical MASH Program

Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.Price: $76.58, Change: $+0.19, Percent Change: +0.25%

$ARWR$MDGL

Track with the FINWIRES app suite

FolioX

Track MDGL in your portfolio

WheelAI

Analyze MDGL options with the wheel strategy

StockInsider

See market sentiment on MDGL